|
FXC1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
2.84640000003389E-06 |
| Normal-vs-Stage3 |
1.99840144432528E-15 |
| Normal-vs-Stage4 |
1.62625468647093E-12 |
| Stage1-vs-Stage2 |
1.799510E-02 |
| Stage1-vs-Stage3 |
4.614600E-01 |
| Stage1-vs-Stage4 |
2.082200E-02 |
| Stage2-vs-Stage3 |
9.602900E-03 |
| Stage2-vs-Stage4 |
2.954300E-04 |
| Stage3-vs-Stage4 |
1.050630E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.06270000002728E-06 |
| Normal-vs-Asian |
2.51500043013664E-10 |
| Caucasian-vs-AfricanAmerican |
3.365000E-01 |
| Caucasian-vs-Asian |
4.169800E-01 |
| AfricanAmerican-vs-Asian |
7.529600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.6242562850266E-12 |
| Male-vs-Female |
7.146000E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
4.44089209850063E-16 |
| Normal-vs-Age(61-80Yrs) |
2.02338146237935E-12 |
| Normal-vs-Age(81-100Yrs) |
1.180610E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.481000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.206200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.534400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.923800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.233200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.302400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.295800E-02 |
| Classical-VS-Follicular |
7.522200E-03 |
| Classical-VS-Other |
6.350400E-02 |
| Classical-VS-Normal |
2.04747330201371E-12 |
| Tall-VS-Follicular |
2.752900E-04 |
| Tall-VS-Other |
2.851200E-01 |
| Tall-VS-Normal |
6.50590692430342E-14 |
| Follicular-VS-Other |
3.038300E-02 |
| Follicular-VS-Normal |
8.78319999952915E-07 |
| Other-VS-Normal |
4.25360000000374E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.42441614059408E-13 |
| Normal-vs-N1 |
3.33066907387547E-16 |
| N0-vs-N1 |
2.377400E-04 |
|
|
